Lakshmanan Krishnamurti, MD Named Chief of Pediatric Hematology, Oncology, and Bone Marrow Transplant
Lakshmanan Krishnamurti, MD has been named chief of pediatric hematology and oncology for Yale’s Department of Pediatrics and Yale New Haven Children’s Hospital effective October 1, 2021. Dr. Krishnamurti is an accomplished pediatric hematologist oncologist and an international leader in bone marrow transplant and the treatment of hemoglobinopathies. He joins us from Atlanta, where he is professor of pediatrics at Emory University School of Medicine and director of the bone marrow transplantation program where he holds the Joseph Kuechenmeister Aflac Field Force Chair at Children’s Healthcare of Atlanta.
One Patient’s Dream of Giving Back Supports 14 Families at Smilow
After spending time talking with other cancer patients during her regular appointments at Smilow Cancer Hospital, Nicole Donzello quickly recognized the stress that many patients and families are under during their treatment. “When diagnosed with cancer, it’s heartbreaking to hear how everything is crumbling around many patients. I heard how some were focused on monetary issues versus their health and the amount of stress it caused for them. Patients really need the freedom to focus on themselves,” Nicole explained.
Bone marrow transplant using fludarabine‐based reduced intensity conditioning regimen with in vivo T cell depletion in patients with Fanconi anemia
FA is the most common cause of inherited BMF syndromes. The only cure for BMF in FA remains HSCT. Due to DNA instability in FA, RIC has been used to decrease immediate and late complications of HSCT.Source: Wiley
An Innovative Treatment Approach for DIPG: CureSearch for Children’s Cancer Partners with SebastianStrong Foundation to Fund Promising New Research
CureSearch for Children’s Cancer, in partnership with the SebastianStrong Foundation, has awarded a $225,000 Young Investigator grant to Yale Cancer Center’s Dr. Ranjithmenon Muraleedharan, who will develop a new treatment approach for diffuse intrinsic pontine glioma (DIPG) – a devastating brain cancer with a 5-year survival rate of less than 1%. The 3-year project is funded by SebastianStrong Foundation’s Discovery Science Award.Source: CureSearch for Children's Cancer
Risk-associated alterations in marrow T cells in pediatric leukemia
Current management of childhood leukemia is tailored based on disease risk determined by clinical features at presentation. Whether properties of the host immune response impact disease risk and outcome is not known.Source: JCI Insight
A Daughter of Immigrant Doctors, Nina Kadan-Lottick, MD, MSPH, Chose a Career in Pediatric Oncology
In 2003, Nina Kadan-Lottick, MD, MSPH, established the regional Yale HEROS multidisciplinary research and clinical program for long-term survivors of childhood cancer survivors, which is the first of its kind in Connecticut and one of the first in the United States. She intends the HEROS program to serve as a test bed for her pilot studies, which she plans to expand into large, multi-institution studies. Along with her directorship of the HEROS program, Dr. Kadan-Lottick is Associate Professor of Pediatric Hematology/Oncology at Yale School of Medicine, New Haven, Connecticut.Source: The ASCO Post
Symptoms of Childhood & Adolescent Cancers
Childhood and adolescent cancers are rare, and early symptoms may seem like everyday bumps, bruises, and infections. Unlike common childhood illnesses and injuries, however, cancer symptoms don't get better on their own. Depending on where the cancer cells gather in the body, a child with cancer will show some symptoms that typically get worse over time.Source: Healthy Children
A COVID-19 Update for our Patients and Families
Smilow Cancer Hospital and our Smilow Cancer Hospital Care Centers are closely monitoring the spread of COVID-19 (Coronavirus) and are taking extra precautions to protect our patients and their families. Patients with cancer often have a weakened immune system, or are immunosuppressed, and are at an increased risk of infection, the flu, and other viruses.
Information for our Patients about COVID–19 from Smilow Cancer Hospital
Smilow Cancer Hospital is closely monitoring the spread of novel coronavirus (COVID-19) and is taking extra precautions to protect our patients and their families. Patients with cancer often have a weakened immune system, or are immunosuppressed, and are at an increased risk of infection, the flu, and other viruses.
Yale School of Medicine Utilizes Virtual Reality Technology to Study a New Era of Group Therapy
Yale School of Medicine in conjunction with Foretell Reality, a subsidiary company of The Glimpse Group, Inc., is actively studying the effects of Virtual Reality (VR) on group therapy for cancer patients.Source: News-Line
Alexa is a happy and healthy teenager thanks to a life-saving stem cell transplant at Smilow Cancer Hospital.
Alexa has a lot of be thankful for this holiday season. She’s healthy following a life-saving stem cell transplant at Smilow Cancer Hospital/Yale New Haven Children's Hospital for Aplastic Anemia that included a very special donor.
A Successful Form of Immunotherapy For Blood Cancers Shows Promise For Other Types of the Disease
An innovative new immunotherapy treatment at the Yale Cancer Center and Smilow Cancer Hospital called CAR T-cell therapy has shown remarkable success in treating certain blood cancers, including some for which all other treatment options have failed.Source: Connecticut Magazine